- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Real-World Outcomes of Initiating Injectable Therapies in Type 2 Diabetes Patients
To date, there has been no real-world comparative data published on the initiation of injectable therapy with insulin glargine disposable pen (GLA-P) of glucagons-like peptide-1 agonist liraglutide (LIRA) among type 2 diabetes patients. On day 1 of the American Diabetes Association's 72nd Scientific Sessions in Philadelphia, PA, an abstract was released by Levin et al which provided data from this exact comparative analysis.
To date, there has been no real-world comparative data published on the initiation of injectable therapy with insulin glargine disposable pen (GLA-P) of glucagons-like peptide-1 agonist liraglutide (LIRA) among type 2 diabetes patients. On day 1 of the American Diabetes Association’s 72nd Scientific Sessions in Philadelphia, PA, an abstract was released by Levin et al which provided data from this exact comparative analysis.
Using the Integrated Health Care Information System’s national managed care claim database, Levin et al assessed 1-year clinical outcomes and plan-paid healthcare costs of T2DM patients failing oral antidiabetic drugs (OADs) and initiating LIRA or GLA-P.
The study was conducted among 336 matched patients that had a mean baseline age of 53 years. Researchers founds that there were no statistically significant differences between GLA-P and LIRA cohorts, A1C reduction from baseline, and percentage of patients achieving A1C <7% among those with follow-up A1C data available. Additionally, researchers reported that hypoglycemia-related event rates were low in both cohorts. However, GLA-P patients had significantly lower study drug costs ($1,198 vs $2,784; P <.001), which resulted in lower diabetes-related healthcare costs ($5,653 vs $7,976; P = .02).
Levn et al concluded that, “among T2DM patients who failed OADs and initiated injectable therapy, GLA-P may be a more cost effective option than LIRA with similar clinical outcomes yet lower diabetes care cost.
To read more about this study, please visit the American Diabetes Association’s website.
Looking Back on ISPOR 2024: Hot Policy Topics, Welcome Focus on Employers, and More
May 10th 2024Kimberly Westrich, MA, chief strategy officer of the National Pharmaceutical Council, reflects on the most valuable learnings from the 2024 meeting of ISPOR—The Professional Society for Health Economics and Outcomes Research, including lively discussions of the Inflation Reduction Act and workshops on value assessment.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Posters Characterize DMD Caregiver Experiences, Impact of Gene Therapy on Caregiving Demands
May 10th 2024Posters presented at the ISPOR—The Professional Society for Health Economics and Outcomes Research meeting explored Duchenne muscular dystrophy (DMD) caregiver experiences and gene therapy’s impact on work opportunities for caregivers.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
Budesonide-Based Triple Therapy Shows Best Benefit Over Dual Therapy for COPD
May 8th 2024The triple therapy of budesonide, glycopyrrolate, and formoterol fumarate showed the greatest incremental net benefit among a series of triple therapy medications that were evaluated against dual therapy for chronic obstructive pulmonary disease (COPD), according to an analysis presented at ISPOR.
Read More
